NDAORALTABLET
Approved
Sep 2012
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Mechanism of Action
Dihydroorotate Dehydrogenase Inhibitors
Pharmacologic Class:
Pyrimidine Synthesis Inhibitor
Clinical Trials (5)
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)
Started Dec 2021
1,001 enrolled
Relapsing Multiple Sclerosis
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)
Started Dec 2021
1,011 enrolled
Relapsing Multiple Sclerosis
Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)
Started Mar 2021
751 enrolled
Relapsing Multiple Sclerosis
Immune Response to COVID-19 Vaccine in Multiple Sclerosis Patients Treated With Teriflunomide and Alemtuzumab
Started Mar 2021
70 enrolled
Multiple Sclerosis
A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)
Started Mar 2021
746 enrolled
Relapsing Multiple Sclerosis
Loss of Exclusivity
LOE Date
Aug 4, 2034
102 months away
Patent Expiry
Aug 4, 2034
Patent Records (5)
| Patent # | Expiry | Type | Use Code |
|---|---|---|---|
| 6794410 | Sep 12, 2026 | U-1285 | |
| 6794410*PED | Mar 12, 2027 | — | |
| 8802735 | Sep 14, 2030 | Product | — |
| 8802735*PED | Mar 14, 2031 | — | |
| 9186346 | Feb 4, 2034 | U-1786 |